Posizioni attive di Joshua Moriarty
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Okogen, Inc.
 Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA. | Direttore/Membro del Consiglio | 02/11/2023 | - |
| Direttore operativo | - | - | |
| Amministratore Delegato | 08/03/2022 | 31/10/2023 |
Storia della carriera di Joshua Moriarty
Statistiche
Distribuzione geografica
| Stati Uniti | 2 |
Posizioni
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| Chief Operating Officer | 1 |
Settori
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Okogen, Inc.
Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA. | Commercial Services |
- Borsa valori
- Insiders
- Joshua Moriarty
- Esperienza
